BioCardia Inc BCDA.OQ reported a quarterly adjusted loss of 6 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -61 cents. The mean expectation of two analysts for the quarter was for a loss of 17 cents per share. Wall Street expected results to range from -20 cents to -21 cents per share.
Reported revenue was zero; analysts expected zero.
BioCardia Inc's reported EPS for the quarter was a loss of 6 cents.
The company reported a quarterly loss of $1.98 million.
BioCardia Inc shares had fallen by 4.0% this quarter.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 35.3% in the last three months.
In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for BioCardia Inc is $25.00, about 95.2% above its last closing price of $1.21
This summary was machine generated from LSEG data March 24 at 09:38 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Dec. 31 2025 | -0.23 | -0.06 | Beat |
Jun. 30 2025 | -0.50 | -0.40 | Beat |
Jun. 30 2025 | -0.50 | -0.40 | Beat |
Mar. 31 2025 | -0.39 | -0.59 | Missed |
Comments